A new trading day began on Tuesday, with Zentalis Pharmaceuticals Inc (NASDAQ: ZNTL) stock price up 0.97% from the previous day of trading, before settling in for the closing price of $3.10. ZNTL’s price has ranged from $2.66 to $18.07 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Healthcare Sector giant saw their annual sales slid by -20.00% over the last five years. Meanwhile, its annual earnings per share averaged 45.10%. With a float of $57.60 million, this company’s outstanding shares have now reached $71.15 million.
The firm has a total of 168 workers. Let’s measure their productivity. In terms of profitability, gross margin is 97.68%, operating margin of -490.5%, and the pretax margin is -419.76%.
Zentalis Pharmaceuticals Inc (ZNTL) Insider Activity
As we move forward, let’s examine how large-scale investors are investing in this stock of the Biotechnology Industry. The insider ownership of Zentalis Pharmaceuticals Inc is 19.17%, while institutional ownership is 83.16%. The most recent insider transaction that took place on Oct 31 ’24, was worth 28,294. Before that another transaction happened on Oct 04 ’24, when Company’s Principal Accounting Officer sold 1,603 for $3.18, making the entire transaction worth $5,098. This insider now owns 33,855 shares in total.
Zentalis Pharmaceuticals Inc (ZNTL) Earnings and Forecasts
According to the Wall Street analysts, stocks earnings will be around 45.10% per share during the next fiscal year.
Zentalis Pharmaceuticals Inc (NASDAQ: ZNTL) Trading Performance Indicators
Here are Zentalis Pharmaceuticals Inc’s current performance indicators. According to the last quarter’s results, the stock had a quick ratio of 7.29. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 5.50.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -2.53, a number that is poised to hit -0.79 in the next quarter and is forecasted to reach -2.93 in one year’s time.
Technical Analysis of Zentalis Pharmaceuticals Inc (ZNTL)
Analysing the last 5-days average volume posted by the [Zentalis Pharmaceuticals Inc, ZNTL], we can find that recorded value of 1.25 million was lower than the volume posted last year of 1.31 million. As of the previous 9 days, the stock’s Stochastic %D was 9.76%. Additionally, its Average True Range was 0.29.
During the past 100 days, Zentalis Pharmaceuticals Inc’s (ZNTL) raw stochastic average was set at 16.91%, which indicates a significant increase from 12.12% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 86.25% in the past 14 days, which was lower than the 89.57% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $3.31, while its 200-day Moving Average is $6.89. Now, the first resistance to watch is $3.24. This is followed by the second major resistance level at $3.34. The third major resistance level sits at $3.44. If the price goes on to break the first support level at $3.04, it is likely to go to the next support level at $2.94. Should the price break the second support level, the third support level stands at $2.84.
Zentalis Pharmaceuticals Inc (NASDAQ: ZNTL) Key Stats
With a market capitalization of 223.06 million, the company has a total of 71,265K Shares Outstanding. Currently, annual sales are 0 K while annual income is -292,190 K. The company’s previous quarter sales were 0 K while its latest quarter income was -88,280 K.
